BUPIVACAINE HYDROCHLORIDE INJECTION, USP SOLUTION

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

BUPIVACAINE HYDROCHLORIDE

Доступно од:

BAXTER CORPORATION

АТЦ код:

N01BB01

INN (Међународно име):

BUPIVACAINE

Дозирање:

2.5MG

Фармацеутски облик:

SOLUTION

Састав:

BUPIVACAINE HYDROCHLORIDE 2.5MG

Пут администрације:

BLOCK/INFILTRATION

Јединице у пакету:

100

Тип рецептора:

Ethical

Терапеутска област:

LOCAL ANESTHETICS

Резиме производа:

Active ingredient group (AIG) number: 0108896001; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2019-05-23

Карактеристике производа

_ _
_Bupivacaine Hydrochloride Injection, USP Product Monograph Page 1 of
35_
PRODUCT MONOGRAPH
BUPIVACAINE HYDROCHLORIDE INJECTION, USP
2.5 mg/mL,
5 mg
/mL and 7.5 mg/mL Bupivacaine Hydrochloride, USP
Sterile Solution
Local Anesthetic
BAXTER CORPORATION
Mississauga, Ontario
L5N 0C2
Date of Preparation:
May 22, 2019
Submission Control No: 210568
_ _
_Bupivacaine Hydrochloride Injection, USP Product Monograph Page 2 of
35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 21
STORAGE AND STABILITY
.........................................................................................
23
SPECIAL HANDLING INSTRUCTIONS
......................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 24
PART II: SCIENTIFIC INFORMATION
..............................................................................
26
PHARMACEUTICAL INFORMATION
..................................................